Understanding RILD's clinical characteristics is essential for effective management in patients undergoing immunochemotherapy ...

Objectives Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into ...

Groundbreaking bone marrow transplant saves 10-month-old boy with rare genetic immunodeficiency, funded by The Hans ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

Tacrolimus, cyclosporin, mycophenolate mofetil, and levamisole may reduce the risk of relapse in children with frequently relapsing nephrotic syndrome. Cyclophosphamide and chlorambucil compared with ...

Background Studies examining the relationship between serological status (rheumatoid factor and/or anticitrullinated antibody) and rituximab treatment outcome in rheumatoid arthritis (RA) have been ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

National register data from patients diagnosed with RA who began treatment with TNF inhibitors, rituximab, abatacept, interleukin (IL)-6 inhibitors, or JAK inhibitors between 2017 and 2019 were ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 40 ...

Results All patients given rituximab achieved BCD. The mean number of flares during follow-up (new BILAG A or B) was 2.63 (SD 3) in the BCDT group and 4 (SD 3.6) in the controls (NS, p=0.14).

Her condition improved following the introduction of glucocorticoids, plasma exchange, and rituximab, with a gradual return to normal values for ADAMTS13 antigen and inhibitory antibodies. The second ...